Arena Pharmaceuticals Inc. ARNA, -3.13% shares jumped 35% in late trading Monday ... group and 20.1% improvement compared with the baseline, the company said. Arena stock topped $25 in after-hours trading immediately following the …
Inc. $ARNA Sees Unusually-High Trading Volume After An.. 07/13 Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock 07/13 BRIEF-Arena Pharmaceuticals says public offering of 6.25 mln common shares pr.. …
Large cap biotech stocks have seen incredible stock performance over the past few years ... Arena Pharmaceuticals Inc. (NASDAQ: ARNA) is a small cap name to buy at Jefferies for 2014. Its approved obesity drug Belviq scripts have …
If a speculative stock moves from $2 to $3 a share, it would be a 50% gain, which would please any speculator. Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) fits both descriptions, which makes it an even more interesting play for stock
Arena Pharmaceuticals, Inc. ARNA is scheduled to report third-quarter 2016 results on Nov 7, after the market closes. The company met earnings expectations last quarter. Over the four trailing quarters, it has recorded an average positive …
Arena Pharmaceutical Inc. (ARNA) reported a second quarter loss of $0.77 after the close Monday, compared to the loss of $1.12 last year. The consensus estimate was for a loss of $0.74. The stock is now down 1.58 on 18K shares. Arena …
Shares of Arena Pharma (Nasdaq: ARNA) are active this morning as we have two different firms downgrading the stock today. Shares moved nicely into the black just after the open, but have now turned negative. At last check, ARNA
Dr. Preston S. Klassen, M.D., M.H.S. as Executive Vice President - Research & Development, Chief Medical Officer of the Company. Dr. Klassen has over 20 years of experience in biopharmaceutical product development. Most recently, he …
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) remains one of the hottest stocks on Wall Street right now making all time highs almost every day. The stock is trading back over all three major moving averages. I like the stock as long as it …
Other options available in the market for obese people include VIVUS, Inc.’s (VVUS - Free Report) Qsymia, Novo Nordisk’s (NVO - Free Report) Saxenda and Arena Pharmaceuticals, Inc.’s (ARNA - Free ... United States. More Stock News: …